The efficacy and safety of the novel oral anticoagulant edoxaban relative to warfarin for stroke prophylaxis are consistent across the full range of systolic blood pressure (SBP) in high-risk patients with atrial fibrillation (AF), according to a posthoc analysis of the ENGAGE AF-TIMI 48 trial.
The potent P2Y12 inhibitor prasugrel significantly reduced the incidence of death, myocardial infarction (MI), or stroke in patients with acute coronary syndrome (ACS) with or without ST-segment elevation (STE) compared with ticagrelor, according to the results of the ISAR-REACT* 5 trial presented at ESC Congress 2019. Moreover, the improved anti-ischaemic efficacy of prasugrel was not accompanied by an increased bleeding risk.
A device-based fluid management system to guide diuretic therapy supports safe and effective regulation of fluid loss in acute heart failure patients with preserved systolic blood pressure and pre-existing chronic renal disease, according to early data from the TARGET-1 and TARGET-2 studies.
A single testing of cardiac troponin I using a high-sensitivity assay can effectively rule out myocardial infarction (MI) without compromising safety, according to the HiSTORIC* study presented at the ESC 2019 Congress.
A newly developed clinical risk score can identify patients with type 2 diabetes (T2D) at greatest risk for hospitalization for heart failure (HHF) who would derive the most benefit from treatment with dapagliflozin, according to a study presented at ESC 2019.
Vegetarian and pescetarian diets are associated with a lower risk of ischaemic heart disease compared with a diet that include meat, according to the longitudinal EPIC*-Oxford study with 18 years of follow-up.
The incidence of cardiovascular disease (CVD)-related deaths is more common in low-income countries (LICs), while cancer-related deaths have increased in high-income countries (HICs) and some middle-income countries (MICs), according to new data from the PURE+ study presented at ESC 2019.
The Malaysian Endocrine and Metabolic Society (MEMS) and Malaysian Diabetes Educators Society (MDES) jointly launched the For Your Sweetheart campaign—a nationwide endeavour to increase public awareness and to educate Malaysians about diabetes-related heart disease.
People with sleep duration shorter than 6 hours/night have an increased risk of myocardial infarction (MI) than those who slept 6–9 hours/night, with additional data from Mendelian randomization supporting a causal link between sleep duration and MI, a new study has shown.
Use of aspirin in the primary prevention of cardiovascular disease (CVD) in patients with no prior CVD history yields protection against the risks of acute myocardial infarction (AMI) and ischaemic stroke, but at the expense of an increase of similar magnitude in the incidence of major bleeding, according to the results of a recent meta-analysis presented at the European Society of Cardiology (ESC) Congress 2019 in Paris, France.
Cardiovascular (CV) outcomes were similar between the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride in the CAROLINA* study of patients with early type 2 diabetes (T2D) and increased CV risk.
A comprehensive model of care delivered by nonphysician health workers (NPHWs), involving primary care physicians and families that was informed by local context, substantially improved blood pressure (BP) control and cardiovascular disease (CVD) risk, according to results of the HOPE 4 trial reported at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.